Equities research analysts expect Evofem Biosciences Inc (NASDAQ:EVFM) to announce earnings of ($0.34) per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Evofem Biosciences’ earnings. The lowest EPS estimate is ($0.43) and the highest is ($0.26). The company is scheduled to issue its next quarterly earnings report on Wednesday, February 6th.
On average, analysts expect that Evofem Biosciences will report full-year earnings of ($5.70) per share for the current fiscal year, with EPS estimates ranging from ($6.78) to ($4.93). For the next year, analysts forecast that the business will report earnings of ($1.55) per share, with EPS estimates ranging from ($1.78) to ($1.35). Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that follow Evofem Biosciences.
Evofem Biosciences (NASDAQ:EVFM) last released its earnings results on Wednesday, November 7th. The biotechnology company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.34).
Several institutional investors and hedge funds have recently bought and sold shares of EVFM. Vanguard Group Inc. acquired a new stake in shares of Evofem Biosciences in the 3rd quarter valued at approximately $879,000. Heartland Advisors Inc. acquired a new stake in shares of Evofem Biosciences in the 3rd quarter valued at approximately $1,319,000. Millennium Management LLC boosted its stake in shares of Evofem Biosciences by 6,497.4% in the 2nd quarter. Millennium Management LLC now owns 733,765 shares of the biotechnology company’s stock valued at $1,989,000 after purchasing an additional 722,643 shares in the last quarter. Finally, Woodford Investment Management Ltd boosted its stake in shares of Evofem Biosciences by 28.5% in the 2nd quarter. Woodford Investment Management Ltd now owns 9,593,197 shares of the biotechnology company’s stock valued at $25,998,000 after purchasing an additional 2,127,659 shares in the last quarter. Institutional investors own 80.49% of the company’s stock.
EVFM opened at $3.20 on Friday. Evofem Biosciences has a 1-year low of $1.79 and a 1-year high of $12.90.
Evofem Biosciences Company Profile
Evofem Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes women's sexual and reproductive health products. Its lead product candidate is Amphora that is in Phase 3 trial for contraception; and in Phase 2b/3 clinical trial for prevention of chlamydia and gonorrhea in women.
See Also: Google Finance
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Evofem Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evofem Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.